GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan
GlaxoSmithKline plc (LSE: GSK) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), administered using the Ellipta™ dry powder inhaler.
The New Drug Application has been submitted to the MHLW for UMEC monotherapy (62.5mcg), as a once-daily inhaled dry powder maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD).
UMEC has recently been granted market authorisation in the US, Canada and in Europe, with the approved trade name Incruse™ Ellipta™. Regulatory filings in other countries will take place throughout 2014 and onwards.
UMEC is not currently approved in Japan and is not licensed anywhere outside of the US, Canada and the European Union.
INCRUSE™ and ELLIPTA™ are trademarks of the GlaxoSmithKline group of companies.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
|
GSK enquiries: |
|||
|
UK Media enquiries: |
David Mawdsley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
David Daley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Catherine Hartley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Sarah Spencer |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
|
|
US Media enquiries: |
Melinda Stubbee |
+1 919 483 2510 |
(North Carolina) |
|
|
Robin Gaitens |
+1 919 483 2678 |
(North Carolina) |
|
|
Juan Carlos Molina |
+1 919 483 0471 |
(North Carolina) |
|
|
Bradd Pavur |
+1 919 483 0044 |
(North Carolina) |
|
|
Karen Collins |
+1 919 483 2527 |
(North Carolina) |
|
|
|||
|
Analyst/Investor enquiries: |
Ziba Shamsi |
+44 (0) 20 8047 3289 |
(London) |
|
Kirsty Collins (SRI CG) |
+44 (0) 20 8047 5534 |
(London) |
|
|
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|
|
Gary Davies |
+44 (0) 20 8047 5503 |
(London) |
|
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
|
|
Lucy Singah |
+44 (0) 20 8047 2248 |
(London) |
|
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013. |
